ATAIHealthcare · Biotechnology

ATAI Stock Forecast: Atai Beckley, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026

$7.26

+0.14% on the day

The 14 Wall Street analysts covering Atai Beckley, Inc. hold a median 12-month price target of $8 — +10.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 26 of 100 as at 13 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap

$2.7B

Ticker Nerd rank

26 / 100

Median analyst target

$8.00

Analysts covering

Total return, dividends reinvested

+0.1%

+28.0%

YTD

+77.5%

+81.0%

From 52W high

0.0%

From 52W low

+116.7%

$3.35

$7.26

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

ATAI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Atai Beckley, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Aug 2026

26 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum

100

Revisions

Accruals

Value

Volatility

Size

Issuance

Growth

Quality

Momentum (100): The shares have been drifting up relative to others.

Quality (7): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ATAI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ATAI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says14 analysts

2 Buy12 Hold0 Sell

Low $7.45Median $8.00High $16.00

The green dot is the last close — the median target sits +10.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 3 moved it down.

Date	Firm	Action	Rating	Target
12 Aug 2026	Deutsche Bank	Downgrade	Hold	$12 → $8.00
20 July 2026	HC Wainwright & Co.	Downgrade	Neutral	$25 → $7.50
20 July 2026	HC Wainwright & Co.	Downgrade	Neutral	—
17 July 2026	Guggenheim	Downgrade	Neutral	—
17 July 2026	Guggenheim	Downgrade	Neutral	—
17 July 2026	Jefferies	Downgrade	Hold	—
17 July 2026	Jefferies	Downgrade	Hold	$10 → $7.50
17 July 2026	Jones Trading	Downgrade	Hold	—
17 July 2026	Jones Trading	Downgrade	Hold	—
16 July 2026	Canaccord Genuity	Downgrade	Hold	$8.00
16 July 2026	Canaccord Genuity	Downgrade	Hold	—
16 July 2026	Maxim Group	Downgrade	Hold	—
16 July 2026	Maxim Group	Downgrade	Hold	—
16 July 2026	Needham	Downgrade	Hold	—
16 July 2026	Needham	Downgrade	Hold	—
7 July 2026	Canaccord Genuity	Maintains	Buy	$15 → $17
7 July 2026	Canaccord Genuity	Maintains	Buy	—
6 July 2026	Jefferies	Maintains	Buy	$10
6 July 2026	Jefferies	Maintains	Buy	—
8 June 2026	HC Wainwright & Co.	Reiterates	Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ATAI appears on the weeks it earns a place.

Estimates

ATAI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Atai Beckley, Inc. (ATAI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −2.5×
Price / sales: 602.5×
Price / book: 13.4×
EV / EBITDA: −17.5×

Growth & margins

Revenue growth (YoY): 137.0%
Earnings growth (YoY): —
Gross margin: —
Operating margin: −2590.4%
Net margin: 0.0%

Returns & dividend

Return on equity: −417.2%
Return on assets: −39.0%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ATAI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
ATAIAtai Beckley, Inc.	$2.7B	26
RAREUltragenyx Pharmaceutical, Inc.	$2.6B	50
TRVITrevi Therapeutics, Inc.	$2.6B	53
BEAMBeam Therapeutics, Inc.	$2.7B	49
NKTRNektar Therapeutics	$2.5B	53
COAGHemab Therapeutics Holdings, Inc.	$2.5B	2
NRIXNurix Therapeutics, Inc.	$2.8B	44

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Atai Beckley, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ATAI news & analysis

Wall Street Analysts Predict a 31.48% Upside in AtaiBeckley Inc (ATAI): Here's What You Should Know

Zacks Investment Research · 7 Aug 2026positive

Wall Street analysts' mean price target for Atai Beckley Inc (ATAI) points to a 31.5% upside in the stock, according to Zacks Investment Research. While the report notes this price-target metric has not proven highly effective historically, strong agreement among analysts in raising earnings estimates suggests a potential upside.

Why it matters — ATAI watchers would care because the report highlights what analyst expectations indicate for the stock and signals that analysts are revising earnings estimates upward.

Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet.

The Motley Fool · 29 July 2026negative

The article reports that Eli Lilly is acquiring Atai Beckley for $2.8 billion, and notes that one of Cathie Wood's funds recently sold some ATAI shares while purchasing shares of Compass Pathways.

Why it matters — ATAI watchers would care because the announcement of a major acquisition by Eli Lilly and a prominent investor's move to sell ATAI and buy a competitor could signal a shift in market views on the company's value.

ATAI Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of AtaiBeckley to Eli Lilly

GlobeNewsWire · 28 July 2026negative

Wohl & Fruchter LLP announced it is investigating whether the proposed sale of AtaiBeckley to Eli Lilly for $6.75 per share in cash plus a contingent value right of up to $2.50 per share is fair to AtaiBeckley shareholders.

Why it matters — The investigation signals potential concerns about whether the deal's terms adequately compensate ATAI shareholders.

FAQ

Frequently asked questions about ATAI stock

What is the ATAI stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Atai Beckley, Inc. have a median 12-month price target of $8, with estimates ranging from $7.45 to $16. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ATAI stock a buy right now?

Of the 14 analysts covering Atai Beckley, Inc., 2 rate it a Buy, 12 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Atai Beckley, Inc. 26 out of 100 across roughly 4,600 US stocks as at 13 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ATAI?

As at 13 Aug 2026, Atai Beckley, Inc. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (100 of 100).

Will ATAI stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +10.2% from the last close, and Ticker Nerd's factor model ranks Atai Beckley, Inc. 26 out of 100 as at 13 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ATAI stock forecast for 2030?

No analyst covering Atai Beckley, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ATAI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7.45 to $16 over the next 12 months.

How has ATAI stock performed over the past year?

Atai Beckley, Inc. returned +81.0% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Atai Beckley, Inc. do?

AtaiBeckley Inc. is a clinical-stage biotechnology company focused on developing innovative treatments for mental health disorders.

What is the latest news on ATAI?

The most recent item we track (Zacks Investment Research, 7 Aug 2026): "Wall Street Analysts Predict a 31.48% Upside in AtaiBeckley Inc (ATAI): Here's What You Should Know". Wall Street analysts' mean price target for Atai Beckley Inc (ATAI) points to a 31.5% upside in the stock, according to Zacks Investment Research. While the report notes this price-target metric has not proven highly effective historically, strong agreement among analysts in raising earnings estimates suggests a potential upside.

Company

About Atai Beckley, Inc.

AtaiBeckley Inc. is a clinical-stage biotechnology company focused on developing innovative treatments for mental health disorders. The company concentrates on psychedelic-based and other novel neuroactive compounds designed to offer rapid-acting, durable, and convenient therapeutic options for people with difficult-to-treat psychiatric conditions, such as treatment-resistant depression, social anxiety disorder, and opioid use disorder. AtaiBeckley operates primarily within the healthcare sector, spanning biotechnology, pharmaceutical research and development, and interventional psychiatry, with research and development activities as its main operational focus. Its pipeline includes investigational therapies like BPL-003, an intranasal 5-MeO-DMT formulation, VLS-01, a DMT buccal film, and EMP-01, an oral R-MDMA candidate, all targeting high-unmet-need mental health indications. Headquartered in New York, United States, and founded in 2025 following the combination of atai Life Sciences and Beckley Psytech, AtaiBeckley today serves as a specialized player in the emerging field of psychedelic-inspired psychiatric therapeutics, aiming to address gaps left by conventional treatments.

CEO Dr. Srinivas G. Rao M.D., Ph.D. · 99 employees · United States · https://www.ataibeckley.com